Zasocitinib

Phase 3Small molecule

Takeda

Zasocitinib is one of 176 small molecule programs targeting Non-segmental Vitiligo. It is currently in Phase 3.

Indications

Total Trials

Active Trials

175

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Segmental VitiligoRecruiting

Palmoplantar PsoriasisNot yet recruiting

Crohn's DiseaseRecruiting

PsoriasisActive, not recruiting

Ulcerative ColitisRecruiting

Psoriatic ArthritisRecruiting

Hidradenitis SuppurativaRecruiting

Non-Segmental VitiligoPhase 2

Recruiting

Palmoplantar PsoriasisPhase 3

Not yet recruiting

Crohn's DiseasePhase 2

Recruiting

PsoriasisPhase 3

Active, not recruiting

Ulcerative ColitisPhase 2

Recruiting

Psoriatic ArthritisPhase 3

Recruiting

Hidradenitis SuppurativaPhase 2

Recruiting

Competition

Competitive Landscape

107 competitors in Psoriasis

#DrugCompanyPhaseTrials

Daliresp

AstraZeneca

Phase 3

5 2

D-2570

IInventisBio Co., Ltd

Phase 3

4 3

Zasocitinib

Takeda

Phase 3

1 4

TAK-279

Takeda

Phase 3

3 5

Ponvory

VVanda Pharmaceuticals

Phase 3

1 6

SYHX1901

CCSPC Ouyi Pharmaceutical Co., Ltd.

Phase 3

2 7

Vunakizumab (IL-17A Inhibitor)

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

1 8

SHR-1314

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

4 9

HS-10374

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3

3 10

ICP-488

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Non-Segmental Vitiligo

NCT07108283

Q1 2028

Phase 3Recruiting

Psoriatic Arthritis

NCT06671496

Phase 3Recruiting

Psoriatic Arthritis

NCT06671483

Phase 2Recruiting

Hidradenitis Suppurativa

NCT07244263

Phase 2Recruiting

Crohn's Disease

NCT07403968

Q1 2029

Phase 3Not yet recruiting

Palmoplantar Psoriasis

NCT07752108

Clinical

Trials by Indication[1]

Psoriatic Arthritis3 trials

A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001)

Recruiting· Takeda logo

Takeda·Phase 3·NCT06671483·1,088 enrolled

A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002)

Recruiting· Takeda logo

Takeda·Phase 3·NCT06671496·600 enrolled

A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs

Recruiting· Takeda logo

Takeda·Phase 3·NCT07286058·1,182 enrolled

Psoriasis1 trial

A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

Active, not recruiting· Takeda logo

Takeda·Phase 3·NCT06973291·606 enrolled

Ulcerative Colitis1 trial

A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

Recruiting· Takeda logo

Takeda·Phase 2·NCT06764615·183 enrolled

Hidradenitis Suppurativa1 trial

A Study of Zasocitinib in Adults With Hidradenitis Suppurativa

Recruiting· Takeda logo

Takeda·Phase 2·NCT07244263·90 enrolled

Interaction1 trial

A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults

Completed· Takeda logo

Takeda·Phase 1·NCT06793943·78 enrolled

4 more indications

Non-segmental Vitiligo1 trial

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants With Nonsegmental Vitiligo

Recruiting· Takeda logo

Takeda·Phase 2·NCT07108283·200 enrolled

Plaque Psoriasis1 trial

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

Recruiting· Takeda logo

Takeda·Phase 3·NCT07250802·110 enrolled

Palmoplantar Psoriasis1 trial

A Phase 3b, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Moderate-to-severe Non-pustular Palmoplantar Psoriasis (PPPsO)

Not yet recruiting· Takeda logo

Takeda·Phase 3·NCT07752108·40 enrolled

Crohn's Disease1 trial

An Open-Label, Single-Arm, Phase 2a Trial to Evaluate the Safety, Tolerability, PK, and Mechanism of Action of Zasocitinib (TAK-279) in Participants With Active Crohn's Disease

Recruiting· Takeda logo

Takeda·Phase 2·NCT07403968·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Zasocitinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zasocitinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zasocitinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Takeda

Zasocitinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Q1 2029

Trials by Indication[1]

Psoriatic Arthritis3 trials

Psoriasis1 trial

Ulcerative Colitis1 trial

Hidradenitis Suppurativa1 trial

Interaction1 trial

Non-segmental Vitiligo1 trial

Plaque Psoriasis1 trial

Palmoplantar Psoriasis1 trial

Crohn's Disease1 trial

References

Drug Info

Quick Facts

Related News